Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-04-05
2011-04-05
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253060, C514S253130, C514S316000, C514S318000, C544S131000, C544S363000, C544S364000, C544S365000, C544S360000, C546S187000, C546S194000, C540S575000
Reexamination Certificate
active
07919495
ABSTRACT:
To provide a compound usable for treatment of diseases associated with fatty acid amide hydrolase (FAAH), especially for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.We have found that a novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative of the present invention has an excellent effect for increasing an effective bladder capacity, an excellent effect for relieving urinary frequency and an excellent anti-allodynia effect, and is therefore usable for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.
REFERENCES:
patent: 5870472 (1999-02-01), Chang et al.
patent: 7585886 (2009-09-01), Hachiya et al.
patent: 2003/0166644 (2003-09-01), Ebdrup et al.
patent: 2004/0102450 (2004-05-01), Ewing et al.
patent: 2004/0186148 (2004-09-01), Shankar et al.
patent: 2005/0182130 (2005-08-01), Abouabdellah et al.
patent: 2006/0160819 (2006-07-01), Hansen et al.
patent: 2006/0160820 (2006-07-01), Hansen et al.
patent: 2006/0160851 (2006-07-01), Ebdrup et al.
patent: 2006/0247290 (2006-11-01), Abouabdellah et al.
patent: 2006/0293310 (2006-12-01), Abouabdellah et al.
patent: 2007/0021405 (2007-01-01), Abouabdellah et al.
patent: 2007/0021424 (2007-01-01), Abouabdellah et al.
patent: 2007/0027141 (2007-02-01), Abouabdellah et al.
patent: 2007/0219187 (2007-09-01), Bessis et al.
patent: 2184919 (1996-07-01), None
patent: 2370411 (2002-08-01), None
patent: 0 477 903 (1992-04-01), None
patent: 4-261157 (1992-09-01), None
patent: 9-510974 (1997-11-01), None
patent: 9-511764 (1997-11-01), None
patent: 2001-503778 (1998-05-01), None
patent: 2002-541109 (2002-12-01), None
patent: 2003-192659 (2003-09-01), None
patent: WO 95/26337 (1995-10-01), None
patent: WO 96/21648 (1996-07-01), None
patent: WO 98/20893 (1998-05-01), None
patent: WO 99/37304 (1999-07-01), None
patent: WO 00/59510 (2000-10-01), None
patent: WO 01/07436 (2001-02-01), None
patent: WO 02/43762 (2002-06-01), None
patent: WO 03/051841 (2003-06-01), None
patent: WO 03/055848 (2003-07-01), None
patent: WO 03/065989 (2003-08-01), None
patent: WO 2004/020430 (2004-03-01), None
patent: WO 2004/033422 (2004-04-01), None
patent: WO 2004/085385 (2004-10-01), None
patent: WO 2004/111004 (2004-12-01), None
patent: WO 2004/111007 (2004-12-01), None
patent: WO 2004/111032 (2004-12-01), None
patent: WO 2005/044797 (2005-05-01), None
patent: WO 2005/070910 (2005-08-01), None
patent: WO 2005/077898 (2005-08-01), None
patent: WO 2005/090322 (2005-09-01), None
patent: WO 2005/090347 (2005-09-01), None
Seierstad et al. J.Med. Chem. vol. 51, p. 7327-7343 (2008).
James D. Leggett, et al. “Oleamide is a selective endogenous agonist of rat and human CB1cannabinoid receptors,” British Journal of Pharmacology (2004) 141, pp. 253-262, 2004 Nature Publishing Group.
Indonesian Office Action dated Nov. 2, 2010 (2 pgs.); English translations dated Feb. 11, 2010 (2 pgs.).
Chinese Office Action, issued in CN Application No. 200680004214.X on Feb. 12, 2010 (4 pages).
Korean Office Action, issued in KN Application No. 10-2007-7020924 on Mar. 15, 2010 (5 pages).
Korean Office Action, issued in KN Application No. 10-2009-7011570 on Mar. 15, 2010 (5 pages).
Korean Office Action, issued in KN Application No. 10-2009-7011569 on Mar. 15, 2010 (5 pages).
Robert B. Angier et al., “Antiviral Agents. I. Analogs and Derivatives of 2-Diethylaminoethyl 4-Methylpiperazine-1-carboxylate”, Organic Chemical Research Section, Lederle Laboratories Division, American Cyanamid Co., Pearl River, NY 10965, vol. 11, pp. 720-729. J. Med. Chem. (1968).
Franze Effenberger et al., “2(1H)-Pyridon als Austrittsgruppe bei Acylierungsreaktionen-Anwendungen in der Peptidchemie”, Chem. Ber. 118, 468-482 (1985).
Franze Effenberger et al., “2(1H)-Pyridon als Austrittsgruppe bei Acylierungsreaktionen-Anwendungen in der Peptidchemie”, Chem. Ber. 118, 468-482 (1985).
P.H. Reggio, “Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors”, Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 66, pp. 143-160, (2002).
M. Montero et al., “Calcineurin-independent inhibition of mitochondrial Ca2+uptake by cyclosporin A”, British Journal of Pharmacology (2004) 141, 263-268.
Benjamin F. Cravatt et al., “Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides”, Nature, vol. 384, Nov. 1996, pp. 83-87.
Christopher J. Fowler et al., “Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide”, Biochemical Pharmacology 62 (2001 pp. 517-526.
Roger G. Pertwee, “Pharmacology of Cannabinoid Receptor Ligands”, Current Medicinal Chemistry, 1999, vol. 6, No. 8, pp. 635-664.
Natalia Dmitrieva et al., “Contrasting Effects of WIN 55212-2 on Motility of the Rat Bladder and Uterus”, The Journal of Neuroscience, Aug. 15, 2002, 22(16): 7147-7153.
Siân I. Jaggar et al., “The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain”, Pain 76 (1998, pp. 189-199.
Satish Kathuria et al., “Modulation of anxiety through blockade of anandamide hydrolysis”, Nature Medicine, vol. 9, No. 1, Jan. 2003, pp. 76-81.
Japanese Office Action, issued in JP Application No. P2007-503689 on May 24, 2010 (3 pages).
Non-Final Office Action issued in U.S. Appl. No. 12/543,690, Date Mailed: May 27, 2010.
Abstract of Zhumal Prikladnoi Khimii, 1995, pp. 675-679, vol. 68(4), Prozorovskii et al.
Non-Final Office Action issued in U.S. Appl. No. 12/543,659, Date Mailed: Jul. 9, 2010.
Second Chinese Office Action, issued in CN Application No. 200680004214.X on Sep. 20, 2010, (2 pages).
Japanese Office Action (Decision of Refusal), issued in JP Application No. P2007-503689 on Sep. 22, 2010 (2 pages).
Korean Office Action (Notice of Preliminary Rejection), issued in KR Application No. 10-2009-7011569 on Nov. 13, 2010 (3 pages).
Korean Office Action (Notice of Preliminary Rejection), issued in KR Application No. 10-2009-7011570 on Nov. 13, 2010 (3 pages).
Korean Office Action (Notice of Preliminary Rejection), issued in KR Application No. 10-2007-7020924 on Nov. 13, 2010 (3 pages).
Canadian Office Action, issued in CA Application No. 2,598,294 on Dec. 13, 2010, (4 pages).
Ishii Takahiro
Kakefuda Akio
Kanai Chisato
Kanayama Takatoshi
Maeda Jun
Astellas Pharma Inc.
Bernhardt Emily
Finnegan Henderson Farabow Garrett & Dunner LLP
LandOfFree
Pyridyl non-aromatic nitrogen-containing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridyl non-aromatic nitrogen-containing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridyl non-aromatic nitrogen-containing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2724391